Frederico C Pereira
Overview
Explore the profile of Frederico C Pereira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goncalves M, Rodrigues-Santos P, Januario C, Cosentino M, Pereira F
Int Immunopharmacol
. 2024 Apr;
133:112062.
PMID: 38652967
Parkinson's Disease (PD) is the second most common neurodegenerative disease where central and peripheral immune dysfunctions have been pointed out as a critical component of susceptibility and progression of this...
2.
Goncalves M, Furgiuele A, Rasini E, Legnaro M, Ferrari M, Luini A, et al.
Eur J Pharmacol
. 2024 Feb;
968:176420.
PMID: 38367683
Background: Proinflammatory cytokines powerfully induce the rate-limiting enzyme indoleamine 2, 3-dioxygenase-1 (IDO-1) in dendritic cells (DCs) and monocytes, it converts tryptophan (Trp) into L-kynurenine (KYN), along the kynurenine pathway (KP)....
3.
Lino M, Rondao T, Banerjee A, Aires I, Rodrigues M, Reis T, et al.
Nanoscale
. 2023 Nov;
15(45):18212-18217.
PMID: 37933179
Herein, we investigate the bioactivity of small extracellular vesicles (sEVs), focusing on their local effect in the brain. sEVs from mononuclear cells (MNCs) showed superior effects to sEVs from mesenchymal...
4.
Furgiuele A, Pereira F, Martini S, Marino F, Cosentino M
Clin Transl Immunology
. 2023 Oct;
12(10):e1469.
PMID: 37781343
Parkinson's disease (PD) is a neurodegenerative disease affecting 7-10 million people worldwide. Currently, there is no treatment available to prevent or delay PD progression, partially due to the limited understanding...
5.
Barbosa J, Leal S, Pereira F, Dinis-Oliveira R, Faria J
Pharmaceuticals (Basel)
. 2023 Jan;
16(1).
PMID: 36678582
Tramadol and tapentadol, synthetic opioids commonly prescribed for moderate-to-severe pain, have a unique pharmacology that optimizes their analgesia and safety. However, they are not devoid of risks, presenting addictive, abuse,...
6.
de Oliveira L, Poluceno G, Sampaio T, Constantino L, Costa A, Martins W, et al.
Neurotox Res
. 2022 Nov;
40(6):1924-1936.
PMID: 36441450
Neonatal exposure to general anesthetics has been associated with neurotoxicity and morphologic changes in the developing brain. Isoflurane is a volatile anesthetic widely used in pediatric patients to induce general...
7.
Palavra F, Viana S, Henriques S, Dinis J, Martins J, Madeira M, et al.
Mult Scler Relat Disord
. 2022 May;
63:103886.
PMID: 35597080
Background: Cuprizone (CPZ) is a copper chelator used to produce a reversible oligodendrocytopathy in animals, which has some similarities to the pathology found in human multiple sclerosis (MS). This model...
8.
Ribeiro D, Petrigna L, Pereira F, Muscella A, Bianco A, Tavares P
Int J Mol Sci
. 2021 Aug;
22(16).
PMID: 34445512
(1) Background: One mechanism through which physical activity (PA) provides benefits is by triggering activity at a molecular level, where neurotrophins (NTs) are known to play an important role. However,...
9.
Pereira F
Rev Port Cardiol (Engl Ed)
. 2021 Jul;
40(6):407-408.
PMID: 34274080
No abstract available.
10.
Mota S, Pita I, Aguas R, Tagorti S, Virmani A, Pereira F, et al.
Arch Toxicol
. 2021 Jun;
95(8):2769-2784.
PMID: 34164711
Mitochondrial deregulation has emerged as one of the earliest pathological events in Alzheimer's disease (AD), the most common age-related neurodegenerative disorder. Improvement of mitochondrial function in AD has been considered...